PUBLICATIONS FDA Decisions Expected Drug pipeline for December 2024 November 15, 2024 Your monthly synopsis of new drugs expected to hit the market At Prime Therapeutics (Prime), we have...

Quarterly Drug Pipeline: January 2024 Clinical insights and competitive intelligence on anticipated drugs in development Drug Pipeline Clinical insights and competitive intelligence on anticipated...

Publications Clinical Highlights: April 2025 Your monthly source for drug information highlights. April 29, 2025 Trending topics Results from the double-blind, placebo-controlled SOUL trial...

Insights from Academy of Managed Care Pharmacy (AMCP) Nexus 2023

Cover image for Cell & Gene Pipeline Outlook: November 2025 Tracking the therapies shaping tomorrow’s care Prime Therapeutics /cell-gene-pipeline-outlook-november-2025 About Prime Therapeutics...

Lassen, chief clinical officer at Prime Therapeutics/Magellan Rx, shares insights on GLP-1 weight-loss drugs and evidence-based approaches to providing the kind of care we’d want for our loved ones.

Prime/MRx remains at the forefront of GLP-1 research, presenting weight loss studies at this year’s annual meeting.

Studies include Prime’s GLP-1 obesity research, the impact of social determinants of health and more.